Exhibit 39



DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICE OF INSPECTOR GENERAL



WASHINGTON, DC 20201

KESHIA B. THOMPSON, SENIOR COUNSEL
ADMINISTRATIVE & CIVIL REMEDIES BRANCH
OFFICE OF COUNSEL TO THE INSPECTOR GENERAL
330 INDEPENDENCE AVENUE, S. W.
COHEN BULLDING - ROOM 5527
WASHINGTON, D.C. 20201
TELEPHONE: (202) 205-9573
FACSIMILE: (202) 205-0604
EMAIL: KESHIA. THOMPSON@OIG. HHS. GOV

March 8, 2012

Bert Weinstein Vice President, Corporate Compliance Purdue Pharma, L.P. One Stamford Forum Stamford, CT 06901

Re: Review of Fourth Annual Report

Dear Mr. Weinstein:

We have reviewed the additional information submitted in response to our inquiries regarding the Fourth Annual Report for Purdue Pharma, L.P. (Purdue). Based on our review of this additional information and the information provided in Purdue's Fourth Annual Report, it appears that Purdue was in compliance with the terms of the Corporate Integrity Agreement (CIA) between the Office of Inspector General (OIG) of the Department of Health and Human Services and Purdue during the fourth annual reporting period.

This letter is not intended to affirm that Purdue has implemented an effective compliance program. Purdue is in the best position to determine the effectiveness of its compliance efforts based upon its own particular circumstances (e.g., size, structure, resources, results of internal assessments, etc.). Notwithstanding, during the remaining term of Purdue's CIA, the OIG will continue to evaluate whether Purdue has demonstrated that it is adhering to the requirements of the CIA.

The OIG makes no representations in this letter as to Purdue's practices or conduct that may be the subject of ongoing investigations, if any. Also, our comments do not reflect our assessment of any legal claims that may be made against Purdue in connection with any ongoing or future investigations.


19-23649-shl Doc 2181-18 Filed 12/21/20 Entered 12/21/20 16:41:46 Leventhal Ex. 039 Pg 3 of 4

Page 2- Bert Weinstein

As a reminder, Purdue's fifth Annual Report is due no later than **September 30, 2012**. If you have any questions regarding Purdue's CIA requirements, please contact me at (202) 205-9573.

Sincerely,

Keshia B. Thompson Senior Counsel



Office of Inspector General 330 Independence Avenue, S.W. Washington, D.C. 20201

Official Business Penalty for Private Use \$300

Bert Weinstein Vice President, Corporate Compliance Purdue Pharma, L.P. One Stamford Forum



0004283863

\$ 00.45° MAR 09 2012

MAILED FROM ZIPCODE 20099

~ossoi+ssi

Stamford, CT 06901

Madle Malland Make Male Mand Malland

DEPARTMENT OF HEALTH AND HUMAN SERVICES

RM 5527-COHEN BLDG.